Premium
Renin Inhibition: A New Approach to Cardiovascular Therapy
Author(s) -
Frishman William H.,
Fozailoff Alan,
Lin Cherry,
Dike Chidiadi
Publication year - 1994
Publication title -
the journal of clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.92
H-Index - 116
eISSN - 1552-4604
pISSN - 0091-2700
DOI - 10.1002/j.1552-4604.1994.tb04000.x
Subject(s) - renin–angiotensin system , pepstatin , renin inhibitor , pharmacology , blood pressure , heart failure , plasma renin activity , bioavailability , medicine , enzyme , angiotensin converting enzyme , enzyme inhibitor , chemistry , biochemistry , protease
The renin‐angiotensin system (RAS) functions as a primary regulator in the short‐term and long‐term control of blood pressure. Pharmacologic inhibition of the RAS with angiotensin‐converting enzyme (ACE) inhibition is effective for treating systemic hypertension and congestive heart failure. As a more specific therapy, the development of renin inhibitors has evolved through various approaches: specific renin antibodies, peptides developed from prosegments of renin precursor, oligopeptides related to pepstatin a universal inhibitor of aspartyl proteinase enzyme, and analogs of angiotensinogen (the renin substrate). Angiotensinogen analogs are promising as therapeutic agents because of high potency, metabolic stability, and good oral bioavailability. Ongoing research is directed towards the application of renin inhibition, the treatment of various cardiovascular disorders, and as a biological probe for understanding the role of the RAS in control of blood pressure and blood volume.